Search Results

AstraZeneca's sign on its office in California

Cancer

AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval

AstraZeneca is seeking a fixed-duration approval for Calquence, which will allow patients with chronic lymphocytic leukemia to take breaks from the therapy and prevent excessive toxicities and drug resistance.

July 30, 2024

·

2 min read

·

Tristan Manalac

Press Releases

New and updated data for Roche’s fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

December 10, 2024

·

12 min read

Press Releases

New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma

December 9, 2024

·

19 min read

Pictured: Teva Pharmaceuticals USA headquarters in

Legal

Teva to Pay $450M in Settlement With DOJ Over Kickback and Price-Fixing Allegations

The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred prosecution agreement.

October 11, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

December 9, 2024

·

16 min read

Press Releases

Prolocor and Slingshot Biosciences Announce Publication of ‘Assessing Prognosis by Quantifying FcγRIIa on Fixed Platelets’ in Bioanalysis

September 5, 2024

·

4 min read

Press Releases

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

November 20, 2024

·

13 min read

Biotech Bay

BioConsortia Expands Nitrogen-fixing Microbial Products for Row Crops to New Territories and New Product Concepts based on Extended Shelf, On-seed Life

BioConsortia, Inc. announced that the Company has further developed its nitrogen-fixing products in row crops, demonstrating through hundreds of field trials conducted in 2023 that the products effectively displace meaningful levels of nitrogen fertilizer and deliver yield gains.

February 20, 2024

·

4 min read

Vector Illustration of pharmacy drug health tablet pharmaceutical, Realistic pills blister pack medical tabs. Eps 10 Vector.

Policy

Pushback Against IRA’s Controversial ‘Pill Penalty’ Faces Stiff Budgetary Headwinds

The EPIC Act has been proposed with bipartisan and industry support to give small molecule drugs the same protection against price negotiation as biologics, but concerns over how to balance the federal budget could prevent a short-term fix to the IRA.

December 11, 2024

·

5 min read

·

Ben Hargreaves

Press Releases

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin

September 5, 2024

·

9 min read